Central Microscopy Microscopy remains central to both laboratory and clinical cancer research. The principal goal of the Central Microscopy Research Facility (CMRF) is to provide services and instruction to HCCC investigators interested in using microscopy technology for cancer research. The CMRF provides technical assistance for labor intensive techniques and ready access to highly specialized and expensive equipment. It supports cancer research being done by members of all 6 research programs. Specific services available to HCCC investigators include expertise related to tissue preparation, fixation and staining for: 1) Light microscopy 2) Histochemical and fluorescence microscopy 3) Confocal, multiphoton and electron microscopy 4) In situ hybridization 5) Elemental and chemical characterization 5) In vivo small animal imaging using the IVIS imaging system The CMRF provides consultation and assistance to HCCC investigators in the development and application of new and specialized morphological methods relevant to cancer research. In 2009, 80 HCCC members with peer reviewed funding utilized the CMRF.

Public Health Relevance

Light, fluorescence, confocal, and electron microscopy are central tools for many aspects of laboratory and clinical cancer research. The CMRF provides a comprehensive, state-of-the-art array of microscopy instrumentation and techniques to HCCC members conducting cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA086862-12S1
Application #
8533964
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2016-03-31
Budget Start
2012-05-03
Budget End
2013-03-31
Support Year
12
Fiscal Year
2012
Total Cost
$3,000
Indirect Cost
$1,013
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Mayo, Zachary; Seyedin, Steven; Marquardt, Michael et al. (2018) Cutaneous malignant melanoma of the oral cavity following skin graft reconstruction: Case report. Head Neck :
D'Angelo, Sandra P; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol 19:416-426
McMaster, Mary L; Berndt, Sonja I; Zhang, Jianqing et al. (2018) Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun 9:4182
Beck, Anna C; Goffredo, Paolo; Hassan, Imran et al. (2018) Risk factors for 30-day readmission after adrenalectomy. Surgery 164:766-773
Gorman, Jacob V; Colgan, John D (2018) Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function. Immunology 154:418-433
El-Galaly, Tarec Christoffer; Cheah, Chan Yoon; Bendtsen, Mette Dahl et al. (2018) Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer 93:57-68
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Xiu, Yan; Dong, Qianze; Li, Qingchang et al. (2018) Stabilization of NF-?B-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia. Cell Rep 22:350-358
Armer, Jessica S; Clevenger, Lauren; Davis, Lauren Z et al. (2018) Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Cancer 124:3401-3408
Spencer Noakes, T Leigh; Przybycien, Thomas S; Forwell, Amanda et al. (2018) Brain Development and Heart Function after Systemic Single-Agent Chemotherapy in a Mouse Model of Childhood Leukemia Treatment. Clin Cancer Res 24:6040-6052

Showing the most recent 10 out of 1080 publications